Introduction
Patients with chronic renal disorders may benefit from annual vaccination against influenza A and B viruses as excess mortality due to epidemic influenza has been reported in this group 1. Protection provided by inactivated whole virus, split or subunit influenza vaccines is mainly associated with the evocation of high antibody titres against viral haemagglutinin (HA)2; the role of simultaneously stimulated cellular immunity is less clear. Patients with chronic renal failure have an impaired cellular and humoral immunity (for review see 3) which might also affect seroresponsiveness to vaccines. The immunogenicity of influenza vaccine has • • 45 been studied in patients with glomerular diseases • and patients on haemodialysis 5-8, and also in kidney transplant recipients 7'9-13. While the safety of the vaccine in these patient groups was established, varying results were obtained in reaching a satisfactory humoral response. However, in most studies small numbers of patients were involved. Recently, an evidently impaired seroresponse to influenza vaccine has been described in 4014 and 2915 patients on haemodialysis. In the present study, the anti-HA-antibody production of trivalent influenza vaccine in a large number of patients on haemodialysis has been evaluated. The influence of the patients' age and the duration of the dialysis treatment on antibody response was studied.
Materials and methods

Study population
One hundred and sixty five subjects were included in the study. The group of patients on intermittent maintenance haemodialysis (HD) consisted of 108 patients (53 males and 55 females), aged 17 to 76 years. In 18 patients (17%), the underlying disorder leading to ends*age renal failure was of immunological origin• 
Laboratory investigations and calculations
Sera were separated immediately after blood collection and clotting and kept frozen at -20°C until titration. Influenza virus strains identical to the vaccine components (kindly provided by Dr J.J. Skehel, WHO World Influenza Centre, London, UK) were propagated in embryonated 10 to 12-day-old chicken eggs. Because of the low avidity of the influenza B virus, infectious egg fluids of this strain were treated with ether according to Berlin et al. 1~ , and the watery phase was used in the serologic tests.
Serum haemagglutination-inhibition (HI) titres were 17 determined twice by standard methods simultaneously in pre-and postvaccination sera. Titres were expressed as the reciprocals of the dilution showing 50% haemagglutination inhibition with 3 haemagglutination units of the antigen. From the results of the two determinations per serum and per antigen, the geometric means were used for further calculations. Negative titres (<9) were arbitrarily regarded as 5.
With the method used, protection against infection is associated with an HI-titre of 100 against influenza A 18"19 and 200 for ether-treated influenza B 2°. Separately for each antigen, subjects who had a prevaccination titre above these thresholds, were excluded. The results of the previously unprotected individuals were used for calculation of the following measures. (1) Response rate, i.e. the proportion of subjects who showed a fourfold or greater titre rise after vaccination. (2) Protection rate, i.e. the proportion of subjects exceeding the threshold titre of 100 (influenza A) and 200 (influenza B) respectively, after vaccination. (3) Overall mean fold increase (MFI), i.e. the difference between the logarithmic (logm) geometric mean titres of post-and prevaccination sera. Differences in qualitative measures were tested for significance by the X 2 test and in quantitative measures by the Wilcoxon rank test.
Results
Final groups and clinical reactions
Twenty one subjects did not complete the full course of the vaccination scheme because of performance of a renal transplantation (one HD patient and three PD patients), development of dialysis-associated peritonitis (six PD patients), death for reasons unrelated to the vaccination (three HD patients) or unknown reasons (six HD patients and two control subjects). One hundred and one HD patients, 21 PD patients and 30 control subjects completed the first vaccination (SO + $30), and 98 HD patients, 17 HD patients and 29 control subjects the booster vaccination (S0 + $30 + $60). No major clinical side effects of the vaccine were reported.
Seroresponse to first vaccination
The height of prevaccination titres was inversely related to the height of titre rises after vaccination (not shown). After exclusion of subjects with already protective prevaccination titres for each antigen separately, the HD and PD groups and the control group were tested for differences with regard to geometric means of prevaccination titres, male/female ratio and age. No significant differences were found, and the groups were regarded as comparable.
As shown in Table 1 , the control subjects produced satisfying protection and response rates ranging from 77 to 95% . Results of PD patients were inferior to controls, but no statistical difference could be detected, except for the MFI value for the A-H3N2 component (1.35 versus 1.79, p = 0.02) and the protection rate for the A-H1N1 component (47% versus 84% , p = 0.01). In contrast, the patients on haemodialysis showed a significant impairment for all three vaccine components: only 67, 43 and 56% of 101 HD patients showed 
Variables influencing seroresponse in dialysis patients
The following variables were tested for influencing the responsiveness to the vaccine components in the various groups: duration of dialysis treatment, age, sex and etiology of renal disease (immunological or not).
The latter two did not show any influence. Figure 1 presents the seroresponse of HD patients, expressed as increases in individual titres related to the duration of haemodialysis in years. The distribution remained constant during the first 8 years. The few patients with a longer duration of dialysis more frequently produced higher titre increases, similar to healthy controls.
Therefore, in Table 3 , the serological response is summarized for two classes of HD patients (up to 8 years versus more than 8 years of haemodialysis). Again, there were no significant differences between these classes in respect of male/female ratio, age, prevaccination titres or etiology of renal failure. Indeed, the patients maintained on HD for more than 8 years achieved response and protection rates similar to control subjects, while the rates in the classes with shorter duration were lower. This phenomenon was present for all three antigens, but most distinct for A-H1N1.
A similar analysis for peritoneal dialysis was not appropriate as there was only one PD patient (after exclusion of subjects with high prevaccination titres) whose dialysis treatment had started more than 8 years ago. In the other subjects no correlation between =.
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In the control and PD group, the seroresponse was not influenced by the age of the vaccinees. In HD patients, however, there was a tendency to a decreasing seroresponse with increasing age for all three antigens Subjects protected after booster/subjects unprotected after first vaccination 7/24(29%) 5/66(8%)** 9/60(15%)
Subjects responding after booster/subjects not responding after first vaccination 10/22(45%) 7/49(14%)** -/35(0%)*** aNumber of subjects after exclusion of those with protective prevaccination titres (/>100, influenza A;/>200, influenza B). In total, 98 HD patients received a booster vaccination. Significant differences between groups: **p < 0.01; ***p < 0.001 versus A-H3N2
other two vaccine components, there were no significant differences between the 36-45 year cohort and the other ages.
Effects of booster vaccination
Additional effects of boosting were estimated in those subjects who, after first vaccination, did not respond or did not achieve protective titre levels. As these subjects were scarce in the control and PD group, because of the high primary response and protection rates (Table 1) , analysis was done only for HD patients who had received a booster vaccination (Table 5 ). The results were highly dependent on the vaccine components. While the booster effect was poor with regard to A-H3N2, revealing protection in only 29% of previously unprotected subjects and response in only 45% of previously unresponding subjects, it was even significantly less for A-H1N1 (8 and 14%) and B (19 and 0%). Age, sex, prevaccination titres (SO), etiology of renal disease or duration of haemodialysis did not influence the boosting effect.
Discussion
In this study, persons with high prevaccination titres resulting from possible earlier vaccinations or recent natural infections were excluded because of the poor or absent additional increase of titres in this group 21"22. Moreover, it is of major clinical interest to which extent immunization leads to a protective state in previously unprotected individuals.
Our results, based on a large number of participants, evidently suggest an impaired humoral response to trivalent influenza vaccine in patients on intermittent maintenance haemodialysis which cannot be satisfactorily compensated by a booster injection of the same antigen dosage one month later. This is in accordance with Cappel 7 . However, the number of patients in those studies was small and subjects with high prevaccination titres were included. This might result in underscoring statistically significant differences (jype 2 error), as has been demonstrated by Gross et al. ~-" for studies dealing with a similar issue (influenza vaccination in cancer patients). On the other hand, the comparison with vaccination trials performed in different years should be made cautiously, since the prevalence of prevaccination antibodies against vaccine components, which is a potent factor influencing the seroresponse to vaccination, is annually Changing, dependent on the occurrence of natural influenza seasons.
Patients on peritoneal dialysis, even those with short duration of dialysis, showed a significantly better response than patients on haemodialysis. This issue will be discussed in detail elsewhere.
The duration of haemodialysis treatment was not an important factor influencing the seroresponse. Thus, the initially poor humoral response of renal endstage patients when starting haemodialysis, is not worsened or improved by the treatment within the first 8 years. In six of seven HD patients with a treatment longer than 8 years, a significant 'recovery' of seroresponsiveness was established. This issue should be subject to longitudinal studies including more patients.
In HD patients, the three vaccine components showed remarkable differences in evoking seroresponse. The production of anti-A-H3N2-antibodies was least impaired after both first and booster vaccination. The influenza B and, even more pronounced, the influenza A-H1N1 vaccine component caused less and smaller titre rises, as compared to A-H3N2, after first vaccination, and had virtually no effect as a booster. This could be due to low immunogenicity or an insufficient dosage of these two vaccine components or to a laboratory artifact (low avidity). However, the control subjects revealed results for A-H1N1 and B comparable to the A-H3N2 vaccine component. Alternatively, the discrepancy between A-H3N2 and A-H1N1 can be explained by a failure of the primary response in HD patients. Influenza A subtype H3N2 has been circulating since 1968 causing several epidemics with great impact. It is likely that most of the HD patients have been exposed to A-H3N2 strains before starting the dialysis treatment and even before developing severe renal failure impairing the immune functions. Therefore, the vaccination with the recent A/Philippines/2/ 82(H3N2) virus, except for its new and strain-specific epitopes, is expected to cause an essentially secondary response. Influenza A-H1NI strains related to the vaccine component A/Chile/1/83(H1N1) circulated in [1947] [1948] [1949] [1950] [1951] [1952] [1953] [1954] [1955] [1956] [1957] . People born between 1939 and 1949 had most frequently experienced their first influenza A infection by those strains which resulted in a potent immunological memory for that particular subtype ('priming)24. It could be shown that this age cohort more frequently produced a typical secondary response to a recent A-H1N1 vaccine than the other ages, even after three decades 25. Of the HD patients in this study, in particular this age cohort (36-45 years) reacted well against the A-H1N1 vaccine component. In the other age groups, who had not been primed by A-H1N1, the reappearance of this subtype in 1977 did not produce a significant immunological memory because of its small impact in The Netherlands until now. Moreover, most of the HD patients had already been in an altered immunological state as a result of developing uraemia at that time. The data suggest that the A-H1N1 vaccine component served as a primary antigen in HD patients younger than 36 and older than 45 years and did not evoke optimal response. This would be compatible with findings of Boulton-Jones et al. 26 and Byron et al. 27"2a suggesting that primary humoral response is profoundly depressed in uraemic patients, while secondary response is less depressed. This conclusion is supported by the results of the booster vaccination: in HD patients who had not responded to the first immunization, a better result was gained against the A-H3N2 component as compared to A-H1N1.
The HD patients of this study are comparable with several other subpopulations within the influenza risk group who do not produce protective levels of anti-HAantibody. Beside uraemic and renal transplant patients treated with cyclosporin A 15, these include persons of very high age 29'3° and patients with cancer (for review see 23) . The consequences of these findings for vaccine policy in HD patients are unclear. More frequent booster vaccinations or increased dosages are, in theory, useless in a failing primary humoral immune system. We believe that as long as the causes of depressed humoral response in these patient groups cannot be eliminated, the use of amantadine during 31 ~o influenza A epidemics-and research on live vaccines--and on new generations of vaccine adjuvants 33 should be stimulated.
